Srividhya Ragavan, Author at TradeRx Report

TRIPS

An Open letter to the United States Trade Representative on the TRIPS Waiver

May 19, 2021

May 15, 2021 The Honorable Ambassador Katherine C. Tai United States Trade Representative Executive Office…

Srividhya Ragavan

TRIPS

The India South Africa Proposal: Strengths & Weaknesses

October 29, 2020

On October 2, 2020, India and South Africa jointly tabled a proposal titled Waiver From…

Srividhya Ragavan

TAMU

Executive Education Program on Health, Pharmaceuticals and Intellectual Property

August 28, 2020

Please join us for an Executive Education Program on Health, Pharmaceuticals and Intellectual Property, co-sponsored…

Doris Estelle Long

Srividhya Ragavan

Data Exclusivities Patents

Is it Time to Do Away with Data Exclusivity?

July 8, 2020

If there is a lesson from COVID-19, it is the need to look at the…

Srividhya Ragavan

Jonathan Kimball

IPAB

India’s IPAB Denies Access To A Leukemia Medication In An Unsubstantiated IPAB Order And Creates Uncertainty

June 19, 2020

An interim order of the IPAB from Justice Manmohan Singh & Dr Onkar Nath ensures…

Srividhya Ragavan

COVID-19 TRIPS

COVID-19 Should Change the U.S. Posture on Global Access to Medication

May 18, 2020

The U.S. has long deferred to pharmaceutical companies on questions of pricing and availability of…

Micheal Palmedo

Srividhya Ragavan

COVID-19 TRIPS

COVID-19 Throws Harsh Spotlight on The Human Cost of Misguided International Trade & IP Policies

May 18, 2020

The current global struggle with the Coronavirus pandemic has highlighted dangerous shortcomings of our healthcare…

Srividhya Ragavan

Doris Estelle Long

COVID-19 Trade Policy TRIPS

Coronavirus & Restoring Trade: Access to Healthcare as the Solution

May 18, 2020

The coronavirus pandemic is a global emergency that pertains to health but threatens to destroy…

Srividhya Ragavan

Srividhya Ragavan

An Open letter to the United States Trade Representative on the TRIPS Waiver

The India South Africa Proposal: Strengths & Weaknesses

Executive Education Program on Health, Pharmaceuticals and Intellectual Property

Is it Time to Do Away with Data Exclusivity?

India’s IPAB Denies Access To A Leukemia Medication In An Unsubstantiated IPAB Order And Creates Uncertainty

COVID-19 Should Change the U.S. Posture on Global Access to Medication

COVID-19 Throws Harsh Spotlight on The Human Cost of Misguided International Trade & IP Policies

Coronavirus & Restoring Trade: Access to Healthcare as the Solution

Search

Blog Front Page

Categories

Archives

RECENT POSTS

Regular Contributors